Review Outlines Ongoing Phase 3 Trials of Radiopharmaceutical Therapies

This review describes several ongoing phase 3 randomized trials of radiopharmaceutical therapies (RPTs) expected to yield practice-changing evidence. It covers PSMAcTION, STAMPEDE2, PSMA-DC, and PSMAddition, which evaluate PSMA-directed treatments in prostate cancer, and NETTER-3, ACTION-1, and COMPOSE, which evaluate somatostatin receptor-targeted radiopharmaceuticals in neuroendocrine neoplasms. The authors note that these trials merge nuclear medicine imaging and drug administration procedures with oncology-driven standards of care and endpoint definitions, and that expansion of such trials has been driven by increased industry investment.

Most relevant for: Relevant to patients with prostate cancer or neuroendocrine neoplasms who may be candidates for radiopharmaceutical therapy trials.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.